These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7122480)

  • 1. Mechanism of action of an antithrombotic agent antithrombin III - factor Xa complex.
    Bajwa SS
    Proc West Pharmacol Soc; 1982; 25():1-5. PubMed ID: 7122480
    [No Abstract]   [Full Text] [Related]  

  • 2. A new type of antithrombotic agent: action of antithrombin III - factor Xa complex.
    Bajwa SS
    Proc West Pharmacol Soc; 1981; 24():275-9. PubMed ID: 7255468
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of a sulfated polysaccharide on antithrombin III.
    Czapek EE; Kwaan HC; Szczecinski M
    J Lab Clin Med; 1980 Jun; 95(6):783-90. PubMed ID: 6155418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics of anticoagulation by covalently immobilized heparin.
    Miura Y; Aoyagi S; Kusada Y; Miyamoto K
    J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor X.
    Jackson CM
    Prog Hemost Thromb; 1984; 7():55-109. PubMed ID: 6397768
    [No Abstract]   [Full Text] [Related]  

  • 8. Decreased heparin sensitivity of cyclohexanedione-modified factor Xa.
    Blaskó G; Machovich R
    Thromb Haemost; 1979 Aug; 42(2):556-63. PubMed ID: 505364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 10. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
    Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
    J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits.
    Wessler S; Gitel SN; Bank H; Martinowitz U; Stephenson RC
    Thromb Haemost; 1979 Feb; 40(3):486-98. PubMed ID: 425063
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1979 Sep; 586(3):584-93. PubMed ID: 476156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
    Chan TK; Chan V
    Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of a direct anti-factor Xa activity in certain heparin-related glycosaminoglycans.
    Larsson A; Fransson LA; Lewis WE
    Thromb Res; 1982 Jun; 26(6):401-9. PubMed ID: 7112518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa.
    Taniuchi Y; Sakai Y; Hisamichi N; Kayama M; Mano Y; Sato K; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T
    Thromb Haemost; 1998 Mar; 79(3):543-8. PubMed ID: 9531037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case report of a paroxysmal nocturnal hemoglobinuria with increased coagulation activation markers while on treatment with LMWH with anti-Xa levels above the therapeutic range.
    Arkel YS; Ku DH; Lake C; Lam X; Spielvogel A
    Thromb Haemost; 2000 Feb; 83(2):348-9. PubMed ID: 10739398
    [No Abstract]   [Full Text] [Related]  

  • 19. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK; Mestries JC; Gascon MP; Ythier A
    Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.